Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 1
1991 2
1992 2
1993 2
1994 3
1995 3
1996 9
1997 2
1998 3
1999 3
2000 2
2003 2
2014 1
2015 1
2017 2
2018 3
2020 3
2021 3
2022 3
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for de gooijer c[au]
Your search for de Gooijer H[au] retrieved no results
Immunotherapy in Malignant Pleural Mesothelioma.
de Gooijer CJ, Borm FJ, Scherpereel A, Baas P. de Gooijer CJ, et al. Front Oncol. 2020 Feb 21;10:187. doi: 10.3389/fonc.2020.00187. eCollection 2020. Front Oncol. 2020. PMID: 32154179 Free PMC article. Review.
Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study.
Douma LH, Lalezari F, van der Noort V, de Vries JF, Monkhorst K, Smesseim I, Baas P, Schilder B, Vermeulen M, Burgers JA, de Gooijer CJ. Douma LH, et al. Among authors: de gooijer cj. Lancet Oncol. 2023 Nov;24(11):1219-1228. doi: 10.1016/S1470-2045(23)00446-1. Epub 2023 Oct 13. Lancet Oncol. 2023. PMID: 37844598 Clinical Trial.
Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma.
Dumoulin DW, Douma LH, Hofman MM, van der Noort V, Cornelissen R, de Gooijer CJ, Burgers JA, Aerts JGJV. Dumoulin DW, et al. Among authors: de gooijer cj. Lung Cancer. 2024 Jan;187:107440. doi: 10.1016/j.lungcan.2023.107440. Epub 2023 Dec 14. Lung Cancer. 2024. PMID: 38104353 Free article.
Tumour Treating Fields for mesothelioma.
de Gooijer CJ, Burgers JA. de Gooijer CJ, et al. Lancet Oncol. 2020 Jan;21(1):e9. doi: 10.1016/S1470-2045(19)30828-9. Lancet Oncol. 2020. PMID: 31908313 No abstract available.
Pembrolizumab for the treatment of non-small cell lung cancer.
Muller M, Schouten RD, De Gooijer CJ, Baas P. Muller M, et al. Among authors: de gooijer cj. Expert Rev Anticancer Ther. 2017 May;17(5):399-409. doi: 10.1080/14737140.2017.1311791. Epub 2017 Apr 3. Expert Rev Anticancer Ther. 2017. PMID: 28338376 Review.
Impact of centralization of care for malignant peritoneal mesothelioma: A historical cohort study from the Dutch mesothelioma expert centers.
van Kooten JP, de Gooijer CJ, von der Thüsen JH, Brandt-Kerkhof ARM, Albers AGJ, Lahaye MJ, Monkhorst K, Burgers JA, Aerts JGJV, Verhoef C, Madsen EVE. van Kooten JP, et al. Among authors: de gooijer cj. Eur J Surg Oncol. 2023 Mar;49(3):611-618. doi: 10.1016/j.ejso.2022.10.003. Epub 2022 Oct 27. Eur J Surg Oncol. 2023. PMID: 36610896 Free article. Review.
Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC.
Jebbink M, de Langen AJ, Monkhorst K, Boelens MC, van den Broek D, van der Noort V, de Gooijer CJ, Mahn M, van der Wekken AJ, Hendriks L, Hashemi SMS, Paats MS, Dingemans AC, Smit EF. Jebbink M, et al. Among authors: de gooijer cj. JTO Clin Res Rep. 2023 Feb 24;4(4):100481. doi: 10.1016/j.jtocrr.2023.100481. eCollection 2023 Apr. JTO Clin Res Rep. 2023. PMID: 37035409 Free PMC article.
53 results